CT-G20 + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiomyopathy, Hypertrophic Obstructive
Conditions
Cardiomyopathy, Hypertrophic Obstructive
Trial Timeline
Oct 23, 2020 → Nov 22, 2022
NCT ID
NCT04418297About CT-G20 + Placebo
CT-G20 + Placebo is a phase 1 stage product being developed by Celltrion for Cardiomyopathy, Hypertrophic Obstructive. The current trial status is terminated. This product is registered under clinical trial identifier NCT04418297. Target conditions include Cardiomyopathy, Hypertrophic Obstructive.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04418297 | Phase 1 | Terminated |
Competing Products
20 competing products in Cardiomyopathy, Hypertrophic Obstructive
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib + Placebo | AMO Pharma | Phase 2 | 44 |
| Mavacamten | LianBio | Phase 1 | 25 |
| Mavacamten + Placebo | LianBio | Phase 3 | 69 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 85 |
| AZD0233 + AZD0233 Placebo | AstraZeneca | Phase 1 | 33 |
| AZD4063 | AstraZeneca | Phase 1 | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| candesartan | AstraZeneca | Phase 2 | 52 |
| LCZ696 + Placebo | Novartis | Phase 2 | 52 |
| Darbepoetin alfa | Amgen | Pre-clinical | 22 |
| Eleclazine + Placebo | Gilead Sciences | Phase 2/3 | 64 |
| Ranolazine | Gilead Sciences | Approved | 84 |
| Ranexa + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine | Gilead Sciences | Pre-clinical | 22 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85